Tigenix gets EMA nod for off-the-shelf stem cell therapy in Crohn’s disease – BioWorld Online
Business Wire |
Tigenix gets EMA nod for off-the-shelf stem cell therapy in Crohn's disease
BioWorld Online LONDON – Eight years on from securing the first EMA approval for an autologous cell therapy, Tigenix NV has done it again, getting the nod for the first allogeneic adipose-derived stem cell therapy, Alofisel (Cx601, darvadstrocel), in the treatment of … Takeda and TiGenix announce that Cx601 (darvadstrocel) has received a positive CHMP opinion to treat complex … |
